Cepheid Demonstrates Advantages of PCRplus Solution at AACC 2022
Posted on 27 Jul 2022
Cepheid (Sunnyvale, CA, USA) will be demonstrating the advantages of its PCRplus Solution at the 2022 AACC Clinical Lab Expo. PCRplus is an elevated PCR test category reserved for molecular diagnostic testing solutions that deliver uncompromised accuracy, speed, flexibility, simplicity, and exceptional test design expertise.
The PCRplus Solution comprises one platform and 22 IVD tests that combine accuracy, speed, flexibility, quality, and simplicity. Cepheid offers a growing portfolio of PCRplus respiratory tests that run on its 40,000 GeneXpert systems placed worldwide to deliver rapid, accurate, and actionable respiratory results. The GeneXpert System was built for simple, reference lab quality PCR testing – on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine.
Cepheid’s line of GeneXpert Systems can be configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with two or four modules – meaning up to four different tests can be run at one time. The company’s largest GeneXpert System is configured with up to 80 modules – meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.
Cepheid offers CoV-2 tests that are designed with multiple gene targets to ensure comprehensive virus detection. This test design approach is used in all of Cepheid's Xpert CoV-2 tests to help guard against variants and ensure the test performance healthcare providers have come to rely on. The company has added the latest Xpert Xpress CoV-2plus test to Xpert Xpress CoV-2/Flu/RSV plus and others in its growing portfolio of PCRplus-based Xpert coronavirus tests.
Related Links:
Cepheid